[en] Immune reconstitution may be delayed after CD34-selected compared with unmanipulated autologous peripheral blood stem cell transplantation (PBSCT), resulting in a theoretically increased risk of infections. In a case-control matched study we compared the incidence of infection in 25 recipients of CD34-selected PBSC (CD34 group) and 75 recipients of unmanipulated PBSC (PBSC group) transplants. The population included 52 males and 48 females suffering from non-Hodgkin's lymphoma (n = 32), Hodgkin's disease (n = 8), multiple myeloma (n = 40) or breast cancer (n = 20). Neutrophil engraftment was comparable in the two groups. The actuarial incidence of infection was similar in the two groups (56% vs. 49% at day 30, and 70% vs. 64% at 1 yr respectively). The proportion of patients with 1, 2 or 3 infections, the number of infectious event per patient (1.32 vs. 1.04; NS), the number of infections before day 15 or 30, between days 31 and 100 or after day 100, the risk of varicella-zoster virus or cytomegalovirus infection or disease, or the use of antibiotic or antifungal therapy, were not increased in the CD34 compared with the PBSC group. The main agents responsible for infection were bacteria, particularly gram-positive cocci, in both groups. Bacteremia accounted for 33% of all infectious events in the CD34 group vs. 16% in the PBSC group (P < 0.05). Fungal infections were rare. In conclusion, our results do not support the notion that CD34-selection of the graft is associated with an increased rate of infection after autologous PBSC transplantation. The role of extended infection prophylaxis should be evaluated.
Disciplines :
Hematology
Author, co-author :
Frere, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Pereira-Martins, Maguy ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.
P hilip T G uglielmi C H agenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 1995 333 1540 1545
S chmitz N P fistner B S extro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 2002 359 2065 2071
A ttal M H arousseau JL S toppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 1996 335 91 97
S chmitz N L inch DC D reger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation vs. autologous bone-marrow transplantation in lymphoma patients Lancet 1996 347 353 357
W atanabe T K awano Y W atanabe A T akaue Y Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience Haematologica 1999 84 167 176
B eguin Y B audoux E S autois B et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells Transfusion 1998 38 199 208
S tewart AK V escio R S chiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial J Clin Oncol 2001 19 3771 3779
P eggs KS V erfuerth S P izzey A et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection Biol Blood Marrow Transplant 2003 9 198 205
R utella S P ierelli L S ica S R umi C L eone G Transplantation of autologous peripheral blood progenitor cells: impact of CD34-cell selection on immunological reconstitution Leuk Lymphoma 2001 42 1207 1220
N achbaur D K ropshofer G H eitger A et al. Phenotypic and functional lymphocyte recovery after CD34+-enriched vs. non-T cell-depleted autologous peripheral blood stem cell transplantation J Hematother Stem Cell Res 2000 9 727 736
M alphettes M C arcelain G S aint -M ezard P et al. Evidence for naive T-cell repopulation despite thymus irradiation after autologous transplantation in adults with multiple myeloma: role of ex vivo CD34+ selection and age Blood 2003 101 1891 1897
C rippa F H olmberg L C arter RA et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation Biol Blood Marrow Transplant 2002 8 281 289
F riedman J L azarus HM K oc ON Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation Bone Marrow Transplant 2000 26 831 836
G oerner M W andt H S chafer -E ckart K B irkmann J D enzel T G allmeier WM The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications J Hematother Stem Cell Res 1999 8 387 391
H olmberg LA B oeckh M H ooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation Blood 1999 94 4029 4035
S ica S S ora F C hiusolo P et al. Early viral complications after autologous CD34-selected peripheral blood stem cell transplantation Bone Marrow Transplant 2000 26 587 588
T akeshima M T akamatsu H I ida M M ochizuki Y O kumura H Y oshida T Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation Int J Hematol 1999 70 193 199
S autois B F raipont V B audoux E et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields Haematologica 1999 84 342 349
F rere P H ermanne JP D ebouge MH D e M ol P F illet G B eguin Y Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures Bone Marrow Transplant 2004 33 745 749
C ordonnier C Definitions of infectious diseases and complications after stem cell transplant 2005 Available online at
A scioglu S R ex JH D e P auw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 2002 34 7 14
B earman SI A ppelbaum FR B uckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6 1562 1568
B lume KG T homas ED A review of autologous hematopoietic cell transplantation Biol Blood Marrow Transplant 2000 6 1 12
J assak PF R iley MB Autologous stem cell transplant: an overview Cancer Pract 1994 2 141 145
K olbe K D omkin D D erigs HG B hakdi S H uber C A ulitzky WE Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation Bone Marrow Transplant 1997 19 143 147
G oldman JM S chmitz N N iethammer D G ratwohl A Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1998 21 1 7
B arton T C ollis T S tadtmauer E S chuster M Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer Clin Infect Dis 2001 32 391 395
M aeda S K agami Y O gura M et al. CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications Int J Hematol 2001 74 214 221
D e R osa L A nghel G P andolfi A R iccardi M A modeo R M ajolino I Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation Int J Hematol 2004 79 85 91
G andhi M J estice H S cott M et al. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis Bone Marrow Transplant 1999 24 369 375
N ash RA D ansey R S torek J et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases Biol Blood Marrow Transplant 2003 9 583 591
R eich G M apara MY R eichardt P D orken B M aschmeyer G Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors Bone Marrow Transplant 2001 27 525 529
S alazar R S ola C M aroto P et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1999 23 27 33
T oor AA V an B urik JA W eisdorf DJ Infections during mobilizing chemotherapy and following autologous stem cell transplantation Bone Marrow Transplant 2001 28 1129 1134
P owell JL B unin NJ C allahan C A plenc R G riffin G G rupp SA An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma Bone Marrow Transplant 2004 33 651 657
